Invivyd Advances COVID-19 Vaccine Alternative, Bolsters Cash Reserves
Event summary
- Invivyd reported Q4 2025 PEMGARDA net product revenue of $17.2 million, a 25% year-over-year increase.
- The company ended 2025 with $226.7 million in cash and cash equivalents following over $200 million in financing.
- Phase 3 DECLARATION trial for VYD2311, a vaccine-alternative antibody, is fully enrolled and has received FDA Fast Track designation.
- An IDMC review of DECLARATION trial data allowed enrollment of pregnant and breastfeeding women, and a potential trial resizing decision is expected in April.
The big picture
Invivyd is positioning itself as a key player in the evolving landscape of COVID-19 prevention, moving beyond traditional vaccination with an antibody-based alternative. The company’s significant cash reserves and ongoing clinical trials represent a substantial investment in this strategy, but success hinges on navigating regulatory hurdles and demonstrating a clear clinical and commercial advantage over existing vaccines. The IDMC’s decision to allow pregnant women in the trial is a positive signal, but the looming resizing decision introduces a significant uncertainty.
What we're watching
- Clinical Trial Progress
- The April resizing decision for the DECLARATION trial will be critical; a downsize could signal efficacy concerns or a need for a revised approach, while an upsize would indicate promising early results.
- Regulatory Landscape
- The FDA’s feedback on the LIBERTY trial, particularly regarding monitoring for myocarditis/pericarditis, suggests heightened scrutiny and could impact the approval pathway for VYD2311.
- Commercial Execution
- While PEMGARDA revenue growth is encouraging, Invivyd’s ability to translate VYD2311’s clinical success into substantial commercial adoption will be key to long-term value creation.
Related topics